Medical professionals need a special DEA waiver to prescribe buprenorphine (a medication-assisted treatment, or MAT, that helps reduce or quit the patients use of heroin or other opiates) to treat substance use disorder, which leads to treatment bottlenecks and a lack of providers.
NDs are highly effective at treating pain with non-pharmacological approaches, but in many states also have authority to prescribe opioids and controlled substances in their scope of practice (OR, AZ, VT, CA).
However, NDs are not currently eligible under federal law to apply for this DEA waiver. The Mainstreaming Addiction Treatment Act of 2019 eliminates the redundant, outdated requirement that practitioners apply for a separate waiver to prescribe buprenorphine for substance use disorder treatment.
If prescribing DEA Schedules III-V is in the scope of practice of naturopathic doctors as defined by state law, then they would be part of the solution to address America’s opioid crisis.
You Can Help!
Send a quick email to your legislators and urge them to support the Mainstreaming Addiction Treatment Act of 2019!